Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04155008 | Nutrition and Pharmacological Algorithm for Oncology Patients Study | terminated | Phase 4 | 1 | Montefiore Medical CenterOTHER | 1 | Nov 16, 2022 |
| clinicaltrials |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | terminated | Phase 2 | 4 | Emory UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02055963 | Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02408887 | Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04128267 | Central Pain Syndrome in Survivors of Head and Neck Cancer | terminated | N/A | 32 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer | terminated | N/A | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03862066 | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | terminated | — | 2 | Medical University of South CarolinaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT00394147 | Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer | terminated | Phase 2 | 17 | Fox Chase Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03065218 | 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients | terminated | Phase 4 | 4 | Medstar Health Research InstituteOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03720158 | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients | terminated | N/A | 9 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents(MLAPOCHI) | terminated | Phase 2 | 1 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03713021 | TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers | terminated | N/A | 27 | Washington University School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04880603 | Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site | terminated | Phase 2 | 5 | Nebraska Methodist Health SystemOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | terminated | Early Phase 1 | 1 | Presage BiosciencesINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma(ICING) | terminated | Phase 2 | 7 | UNICANCEROTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT00198315 | Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma | terminated | Phase 3 | 130 | Inovio PharmaceuticalsINDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01606566 | A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | terminated | Phase 2 | 26 | PCI Biotech ASINDUSTRY | 6 | Feb 18, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT00003777 | Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03937141 | Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer | terminated | Phase 2 | 16 | Chinook Therapeutics, Inc. (formerly Aduro)INDUSTRY | 1 | Jan 3, 2022 | clinicaltrials |
| NCT00566540 | Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer | terminated | Phase 2 | 11 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT04252248 | Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage(DERANO) | terminated | Phase 1 | 3 | University Hospital HeidelbergOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01895829 | Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI | terminated | Early Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | terminated | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03682367 | Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery | terminated | Phase 3 | 8 | University of California, DavisOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03938337 | Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT01126216 | Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer(Paccis-RCT) | terminated | Phase 3 | 221 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | May 4, 2021 | clinicaltrials |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer | terminated | N/A | 8 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT04268329 | Evaluating the Use of an Informational Head and Neck Cancer Website. | terminated | N/A | 14 | University of Illinois at ChicagoOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03729297 | Cabozantinib in Advanced Salivary Gland Cancer Patients(Cabo ASAP) | terminated | Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT00904345 | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | terminated | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT03887442 | Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy(EXTAX) | terminated | Phase 2 | 17 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 0 | Jan 7, 2021 | clinicaltrials |
| NCT03818542 | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 | 3 | AbbVieINDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | terminated | Phase 1 | 6 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02946918 | Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy | terminated | Phase 4 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 1, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 6, 2022source: clinicaltrials